Q3 Earnings Estimate for InflaRx Issued By HC Wainwright

Key Points

• HC Wainwright analysts predict InflaRx will report Q3 2025 earnings of $0.13 per share, maintaining a "Buy" rating with a price target of $6.00.
• InflaRx's stock has an average rating of "Buy" among five analysts, with a consensus target price of $6.20, despite several recent target price reductions by other firms.
• The company reported revenues of $0.05 million in its last earnings release, matching the analysts' expectations, as it continues to develop its lead product candidate, vilobelimab.

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings estimates for InflaRx in a research report issued on Tuesday, September 2nd. HC Wainwright analyst M. Keller expects that the company will earn ($0.13) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $6.00 target price on the stock. The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx's Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.72) EPS.

Other equities research analysts have also recently issued research reports about the stock. Raymond James Financial cut shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price on the stock. in a report on Thursday, May 29th. Oppenheimer dropped their target price on shares of InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, InflaRx currently has a consensus rating of "Buy" and a consensus target price of $6.20.

InflaRx Stock Performance

Shares of NASDAQ:IFRX traded up $0.01 during trading on Thursday, reaching $1.59. 440,487 shares of the stock traded hands, compared to its average volume of 456,180. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82. The stock has a 50-day moving average of $0.98 and a two-hundred day moving average of $1.13. The stock has a market cap of $106.40 million, a P/E ratio of -1.99 and a beta of 1.43.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.24) EPS for the quarter, meeting analysts' consensus estimates of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.02 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC raised its position in InflaRx by 33.9% in the first quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after acquiring an additional 7,616 shares during the period. XTX Topco Ltd bought a new stake in shares of InflaRx during the 1st quarter valued at $38,000. Concurrent Investment Advisors LLC bought a new stake in shares of InflaRx during the 2nd quarter valued at $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of InflaRx by 158.3% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock valued at $118,000 after purchasing an additional 91,927 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new stake in shares of InflaRx during the 2nd quarter valued at $262,000. 42.39% of the stock is currently owned by institutional investors.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.